Ryan P Coyle
YOU?
Author Swipe
View article: 571. Effects of alcohol use on tenofovir alafenamide metabolites among persons with HIV: Implications from a pharmacokinetic model
571. Effects of alcohol use on tenofovir alafenamide metabolites among persons with HIV: Implications from a pharmacokinetic model Open
Background Tenofovir alafenamide (TAF) is used to treat hepatitis B virus and HIV. TAF undergoes intracellular hydrolysis by carboxylesterase 1 (CES1) in the liver and cathepsin A in peripheral blood mononuclear cells (PBMCs), followed by …
View article: Tenofovir-Diphosphate and Emtricitabine-Triphosphate Adherence Benchmarks in Dried Blood Spots for Persons With HIV Receiving Tenofovir Alafenamide and Emtricitabine–Based Antiretroviral Therapy (QUANTI-TAF)
Tenofovir-Diphosphate and Emtricitabine-Triphosphate Adherence Benchmarks in Dried Blood Spots for Persons With HIV Receiving Tenofovir Alafenamide and Emtricitabine–Based Antiretroviral Therapy (QUANTI-TAF) Open
Background QUANTI-TAF aimed to establish tenofovir-diphosphate (TFV-DP)/emtricitabine-triphosphate (FTC-TP) adherence benchmarks in dried blood spots (DBS) for persons with human immunodeficiency virus (PWH) receiving tenofovir alafenamide…
View article: Demographic and Clinical Characteristics of Persons with HIV with Viral Load:Adherence Mismatch Who Are at Risk of Future Viremia
Demographic and Clinical Characteristics of Persons with HIV with Viral Load:Adherence Mismatch Who Are at Risk of Future Viremia Open
The potency of modern antiretroviral therapy (ART) allows for greater forgiveness to missed doses while still achieving, and maintaining, viral suppression. However, imperfect ART adherence, even if sufficient to maintain viral suppression…
View article: Cumulative tenofovir diphosphate exposure in persons with <scp>HIV</scp> taking single‐ vs. multiple‐tablet regimens
Cumulative tenofovir diphosphate exposure in persons with <span>HIV</span> taking single‐ vs. multiple‐tablet regimens Open
Background We assessed cumulative antiretroviral exposure—using tenofovir diphosphate (TFV‐DP) in dried blood spots (DBS)—in persons with HIV (PWH) receiving tenofovir disoproxil fumarate (TDF)‐based antiretroviral therapy (ART) as single‐…
View article: Low-Level Viremia Is Associated With Cumulative Adherence to Antiretroviral Therapy in Persons With HIV
Low-Level Viremia Is Associated With Cumulative Adherence to Antiretroviral Therapy in Persons With HIV Open
The drivers of low-level viremia (LLV) between 20 and 200 copies/mL remain unclear. In 1042 person-visits from 497 persons with HIV on tenofovir disoproxil fumarate–containing antiretroviral therapy (ART), the association between LLV and c…
View article: Emtricitabine triphosphate in dried blood spots predicts future viremia in persons with HIV and identifies mismatch with self-reported adherence
Emtricitabine triphosphate in dried blood spots predicts future viremia in persons with HIV and identifies mismatch with self-reported adherence Open
Objective: Emtricitabine triphosphate (FTC-TP) in dried blood spots (DBS), a measure of short-term antiretroviral therapy (ART) adherence, is associated with viral suppression in persons with HIV (PWH). However, its ability to predict futu…
View article: A Brief Training Program to Support the Use of a Digital Pill System for Medication Adherence: Pilot Descriptive Study
A Brief Training Program to Support the Use of a Digital Pill System for Medication Adherence: Pilot Descriptive Study Open
Background Digital pill systems (DPSs), which comprise ingestible radiofrequency sensors integrated into a gelatin capsule that overencapsulates a medication, can directly measure ingestion events. Objective Teaching users to operate a DPS…
View article: Higher medication complexity in persons with HIV is associated with lower tenofovir diphosphate in dried blood spots
Higher medication complexity in persons with HIV is associated with lower tenofovir diphosphate in dried blood spots Open
Study Objective To assess the association between tenofovir diphosphate (TFV‐DP) in dried blood spots (DBS), a measure of cumulative tenofovir‐based antiretroviral (ART) adherence, with medication regimen complexity in persons with human i…
View article: A Brief Training Program to Support the Use of a Digital Pill System for Medication Adherence: Pilot Descriptive Study (Preprint)
A Brief Training Program to Support the Use of a Digital Pill System for Medication Adherence: Pilot Descriptive Study (Preprint) Open
BACKGROUND Digital pill systems (DPSs), which comprise ingestible radiofrequency sensors integrated into a gelatin capsule that overencapsulates a medication, can directly measure ingestion events. OBJECTIVE Teaching users to operate a …
View article: Associations Between Tenofovir Diphosphate in Dried Blood Spots, Impaired Physical Function, and Fracture Risk
Associations Between Tenofovir Diphosphate in Dried Blood Spots, Impaired Physical Function, and Fracture Risk Open
Background In this study, we evaluate associations between cumulative antiretroviral adherence/exposure, quantified using tenofovir diphosphate (TFV-DP) in dried blood spots (DBS), and human immunodeficiency virus (HIV)-related aging facto…
View article: Income Inequality Is Associated With Low Cumulative Antiretroviral Adherence in Persons With Human Immunodeficiency Virus
Income Inequality Is Associated With Low Cumulative Antiretroviral Adherence in Persons With Human Immunodeficiency Virus Open
Background The adherence biomarker tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) is associated with viral suppression and predicts future viremia. However, its association with social determinants of health (SDoH) in people wit…
View article: Lower Cumulative Antiretroviral Exposure in People Living With HIV and Diabetes Mellitus
Lower Cumulative Antiretroviral Exposure in People Living With HIV and Diabetes Mellitus Open
Objective: People living with HIV (PLWH) are living longer and developing more non-AIDS comorbidities, which negatively impact antiretroviral therapy (ART) adherence. Tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) is a novel pha…
View article: Factors associated with tenofovir diphosphate concentrations in dried blood spots in persons living with HIV
Factors associated with tenofovir diphosphate concentrations in dried blood spots in persons living with HIV Open
Objectives To determine factors associated with interindividual variability in tenofovir diphosphate (TFV-DP) concentrations in dried blood spots (DBSs) among persons living with HIV (PLWH). Methods PLWH who were at least 18 years old and …
View article: Short Communication: Cascade of Antiretroviral Therapy Adherence in Virologically Suppressed Persons Living with HIV
Short Communication: Cascade of Antiretroviral Therapy Adherence in Virologically Suppressed Persons Living with HIV Open
Variable adherence to antiretroviral therapy (ART) can maintain HIV viral suppression, but our understanding of the ART adherence continuum remains limited. In a clinical cohort of adult persons living with HIV treated with a tenofovir (TF…
View article: Predictive Value of Tenofovir Diphosphate in Dried Blood Spots for Future Viremia in Persons Living With HIV
Predictive Value of Tenofovir Diphosphate in Dried Blood Spots for Future Viremia in Persons Living With HIV Open
Background Tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) is associated with viral suppression in persons living with HIV (PLWH) taking tenofovir disoproxil fumarate (TDF). However, its value as a predictor of future viremia rem…
View article: Moderately High Tenofovir Diphosphate in Dried Blood Spots Indicates Drug Resistance in Viremic Persons Living with HIV
Moderately High Tenofovir Diphosphate in Dried Blood Spots Indicates Drug Resistance in Viremic Persons Living with HIV Open
Background: Tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) is a strong predictor of viral suppression in persons living with HIV (PLWH). Its association with antiretroviral therapy (ART) resistance remains unknown. Methods: Bloo…
View article: Emtricitabine triphosphate in dried blood spots is a predictor of viral suppression in HIV infection and reflects short-term adherence to antiretroviral therapy
Emtricitabine triphosphate in dried blood spots is a predictor of viral suppression in HIV infection and reflects short-term adherence to antiretroviral therapy Open
In PLWH, FTC-TP from DBS is a strong predictor of viral suppression, even after adjusting for tenofovir diphosphate, and was best predicted by 3 day self-reported adherence.
View article: Tenofovir Diphosphate in Dried Blood Spots Is Strongly Associated With Viral Suppression in Individuals With Human Immunodeficiency Virus Infections
Tenofovir Diphosphate in Dried Blood Spots Is Strongly Associated With Viral Suppression in Individuals With Human Immunodeficiency Virus Infections Open
Background Although tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) is a predictor of adherence and pre-exposure prophylaxis efficacy, its utility in human immunodeficiency virus (HIV) treatment remains unknown. Methods DBS for T…